Chemical: Drug
sulfamethoxazole

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for sulfamethoxazole,trimethoprim and G6PD
  2. HCSC Label for sulfamethoxazole,trimethoprim and G6PD

last updated 01/15/2014

1. FDA Label for sulfamethoxazole,trimethoprim and G6PD

Actionable PGx

Summary

Sulfamethoxazole and trimethoprim is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals.

Annotation

Although the sulfamethoxazole and trimethoprim (Bactrim) drug label does not specifically mention genetic testing, the FDA highlight precaution labeling for G6PD deficient individuals due to risk of hemolysis.

Excerpt from the sulfamethoxazole and trimethoprim (Bactrim) drug label:

In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. This reaction is frequently dose-related (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the sulfamethoxazole and trimethoprim drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Bronchitis, Chronic
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Diarrhea
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Dysentery, Bacillary
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Otitis Media
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Pneumonia, Pneumocystis
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Seizures
    • Adverse reactions section
    • source: PHONT
  • Urinary Tract Infections
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • ABCB1
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • CYP2C8
    • metabolism/PK, Precautions section
    • source: U.S. Food and Drug Administration
  • CYP2C9
    • metabolism/PK, Clinical pharmacology section, Precautions section
    • source: U.S. Food and Drug Administration
  • G6PD
    • toxicity, Precautions section
    • source: U.S. Food and Drug Administration
  • SLC22A1
    • metabolism/PK, Clinical pharmacology section
    • source: U.S. Food and Drug Administration
  • SLC22A2
    • metabolism/PK, Clinical pharmacology section, Precautions section
    • source: U.S. Food and Drug Administration

last updated 06/08/2015

2. HCSC Label for sulfamethoxazole,trimethoprim and G6PD

Actionable PGx

Summary

The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.

Annotation

Sulfamethoxazole and trimethoprim (SULFATRIM) is an antibacterial agent. Excerpt from the sulfamethoxazole and trimethoprim (SULFATRIM) product monograph:

In glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. This reaction is frequently dose-related.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the sulfamethoxazole and trimethoprim product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for sulfamethoxazole

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available CA No VIP available G6PD B (wildtype) N/A N/A N/A
No VIP available CA VA G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like N/A N/A N/A
No VIP available CA No VIP available GSTM1 non-null N/A N/A N/A
No VIP available CA VA GSTM1 null N/A N/A N/A
No VIP available No VIP available VA NAT2 *4 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5A N/A N/A N/A
No VIP available No VIP available VA NAT2 *5B N/A N/A N/A
No VIP available No VIP available VA NAT2 *5C N/A N/A N/A
No VIP available No VIP available VA NAT2 *6 N/A N/A N/A
No VIP available No VIP available VA NAT2 *6A N/A N/A N/A
No VIP available No VIP available VA NAT2 *6B N/A N/A N/A
No VIP available No VIP available VA NAT2 *7 N/A N/A N/A
No VIP available No VIP available VA NAT2 *7A N/A N/A N/A
No VIP available No VIP available VA NAT2 *7B N/A N/A N/A
No VIP available No VIP available VA NAT2 *13 N/A N/A N/A
No VIP available No VIP available VA NAT2 *14A N/A N/A N/A
No VIP available No VIP available VA NAT2 *14B N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1041983 NC_000008.10:g.18257795C>T, NC_000008.11:g.18400285C>T, NG_012246.1:g.14041C>T, NM_000015.2:c.282C>T, NP_000006.2:p.Tyr94=, XM_011544358.1:c.282C>T, XP_011542660.1:p.Tyr94=, rs17845484, rs17858364, rs59855457
C > T
SNP
Y94Y
No VIP available No Clinical Annotations available VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available No Clinical Annotations available VA
rs1208 NC_000008.10:g.18258316G=, NC_000008.10:g.18258316G>A, NC_000008.11:g.18400806G=, NC_000008.11:g.18400806G>A, NG_012246.1:g.14562G=, NG_012246.1:g.14562G>A, NM_000015.2:c.803G=, NM_000015.2:c.803G>A, NP_000006.2:p.Arg268=, NP_000006.2:p.Arg268Lys, XM_011544358.1:c.803G=, XM_011544358.1:c.803G>A, XP_011542660.1:p.Arg268=, XP_011542660.1:p.Arg268Lys, rs17126586, rs17845485, rs17858365, rs3181478, rs52821724, rs56599719, rs58999469
G > A
SNP
R268K
No VIP available No Clinical Annotations available VA
rs1799929 NC_000008.10:g.18257994C>T, NC_000008.11:g.18400484C>T, NG_012246.1:g.14240C>T, NM_000015.2:c.481C>T, NP_000006.2:p.Leu161=, XM_011544358.1:c.481C>T, XP_011542660.1:p.Leu161=, rs17595342, rs4646268, rs58882350, rs60310310
C > T
SNP
L161L
No VIP available No Clinical Annotations available VA
rs1799930 NC_000008.10:g.18258103G>A, NC_000008.11:g.18400593G>A, NG_012246.1:g.14349G>A, NM_000015.2:c.590G>A, NP_000006.2:p.Arg197Gln, XM_011544358.1:c.590G>A, XP_011542660.1:p.Arg197Gln, rs17517027, rs17856496, rs4646269, rs60190029, rs61467963
G > A
SNP
R197Q
No VIP available No Clinical Annotations available VA
rs1799931 NC_000008.10:g.18258370G>A, NC_000008.11:g.18400860G>A, NG_012246.1:g.14616G>A, NM_000015.2:c.857G>A, NP_000006.2:p.Gly286Glu, XM_011544358.1:c.857G>A, XP_011542660.1:p.Gly286Glu, rs17693862, rs4646270, rs52802193, rs58803786
G > A
SNP
G286E
No VIP available No Clinical Annotations available VA
rs1801280 NC_000008.10:g.18257854T>C, NC_000008.11:g.18400344T>C, NG_012246.1:g.14100T>C, NM_000015.2:c.341T>C, NP_000006.2:p.Ile114Thr, XM_011544358.1:c.341T>C, XP_011542660.1:p.Ile114Thr, rs4134724, rs56935242
T > C
SNP
I114T
No VIP available No Clinical Annotations available VA
rs45607939 NC_000008.10:g.18258126A>T, NC_000008.11:g.18400616A>T, NG_012246.1:g.14372A>T, NM_000015.2:c.613A>T, NP_000006.2:p.Met205Leu, XM_011544358.1:c.613A>T, XP_011542660.1:p.Met205Leu
A > T
SNP
M205L
No VIP available No Clinical Annotations available VA
rs7284807 NC_000022.10:g.43015387C>G, NC_000022.11:g.42619381C>G, NG_012194.1:g.35019G>C, NM_000398.6:c.*392G>C, NM_001129819.2:c.*392G>C, NM_001171660.1:c.*392G>C, NM_001171661.1:c.*392G>C, NM_007326.4:c.*392G>C, rs58086521
C > G
SNP
No VIP available No Clinical Annotations available VA
rs75160992 NC_000018.10:g.74291863A>C, NC_000018.9:g.71959098A>C, NG_023211.1:g.5124T>G, NM_001190807.2:c.13T>G, NM_001914.3:c.13T>G, NM_148923.3:c.13T>G, NP_001177736.1:p.Ser5Ala, NP_001905.1:p.Ser5Ala, NP_683725.1:p.Ser5Ala, XM_011525835.1:c.13T>G, XP_011524137.1:p.Ser5Ala, XR_245456.1:n.154T>G
A > C
SNP
S5A
No VIP available CA VA
rs761142 NC_000006.11:g.53392108A>C, NC_000006.12:g.53527310A>C, NG_012071.1:g.22724T>G, NM_001197115.1:c.151-4783T>G, NM_001498.3:c.151-4783T>G
A > C
SNP
No VIP available No Clinical Annotations available VA
rs76458556 NC_000022.10:g.43015795C>T, NC_000022.11:g.42619789C>T, NG_012194.1:g.34611G>A, NM_000398.6:c.890G>A, NM_001129819.2:c.821G>A, NM_001171660.1:c.989G>A, NM_001171661.1:c.821G>A, NM_007326.4:c.821G>A, NP_000389.1:p.Arg297His, NP_001123291.1:p.Arg274His, NP_001165131.1:p.Arg330His, NP_001165132.1:p.Arg274His, NP_015565.1:p.Arg274His
C > T
SNP
R297H
No VIP available No Clinical Annotations available VA
rs7663179 NC_000004.11:g.25092357T>C, NC_000004.12:g.25090735T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs77005399 NC_000018.10:g.74292264C>T, NC_000018.9:g.71959499C>T, NG_023211.1:g.4723G>A, NM_001190807.2:c.-389G>A, NM_001914.3:c.-389G>A, NM_148923.3:c.-389G>A, XM_011525835.1:c.-389G>A, XR_245456.1:n.-248G>A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs77499608 NC_000022.10:g.43014916A>G, NC_000022.11:g.42618910A>G, NG_012194.1:g.35490T>C, NM_000398.6:c.*863T>C, NM_001129819.2:c.*863T>C, NM_001171660.1:c.*863T>C, NM_001171661.1:c.*863T>C, NM_007326.4:c.*863T>C
A > G
SNP
No VIP available No Clinical Annotations available VA
rs8190370 NC_000022.10:g.43045295G>A, NC_000022.11:g.42649289G>A, NG_012194.1:g.5111C>T, NM_000398.6:c.21+6C>T
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
  • Apo-Sulfamethoxazole
  • Azo Gantanol
  • Azo-Gantanol
  • Bactrimel
  • Gamazole
  • Gantanol
  • Gantanol-DS
  • Metoxal
  • Radonil
  • SIM
  • Septran
  • Simsinomin
  • Sinomin
  • Sulfamethalazole
  • Sulfamethoxazol
  • Sulfamethoxizole
  • Sulfamethylisoxazole
  • Sulfisomezole
  • Sulpha-Methoxizole
  • Sulphamethalazole
  • Sulphamethoxazol
  • Sulphamethoxazole
  • Sulphamethoxazole BP 98
  • Sulphamethylisoxazole
  • Sulphisomezole
  • Trib
  • Urobak
Brand Mixture Names
  • Apo Sulfatrim DS Tab (Sulfamethoxazole + Trimethoprim)
  • Apo Sulfatrim Pediatric (Sulfamethoxazole + Trimethoprim)
  • Apo Sulfatrim Tab (Sulfamethoxazole + Trimethoprim)
  • Bactrim DS Roche Tab (Sulfamethoxazole + Trimethoprim)
  • Bactrim Roche Inj (Sulfamethoxazole + Trimethoprim)
  • Bactrim Roche Suspension Paediatric (Sulfamethoxazole + Trimethoprim)
  • Bactrim Roche Tab (Sulfamethoxazole + Trimethoprim)
  • Novo-Trimel DS Tab (Sulfamethoxazole + Trimethoprim)
  • Novo-Trimel Oral Sus (Sulfamethoxazole + Trimethoprim)
  • Novo-Trimel Tab (Sulfamethoxazole + Trimethoprim)
  • Protrin DF Tab (Sulfamethoxazole + Trimethoprim)
  • Protrin Tab (Sulfamethoxazole + Trimethoprim)
  • Riva-Sep DS (Sulfamethoxazole + Trimethoprim)
  • Roubac Tab 160/800 (Sulfamethoxazole + Trimethoprim)
  • Roubac Tab 80/400 (Sulfamethoxazole + Trimethoprim)
  • Septra (Sulfamethoxazole + Trimethoprim)
  • Septra DS Tablets (Sulfamethoxazole + Trimethoprim)
  • Septra Injection (Sulfamethoxazole + Trimethoprim)
  • Septra Pediatric Suspension (Sulfamethoxazole + Trimethoprim)
  • Sulfamethoxazole and Trimethoprim Tablets (Sulfamethoxazole + Trimethoprim)

PharmGKB Accession Id

PA451544

Type(s):

Drug

Description

A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)

Source: Drug Bank

Indication

For the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.

Source: Drug Bank

Pharmacology

Sulfamethoxazole is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethoxazole is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA. Sulfamethoxazole is normally given in combination with Trimethoprim, a dihydrofolate reductase inhibitor, which inhibits the reduction of dihydrofolic acid to tetrahydrofolic acid. Studies have shown that bacterial resistance develops more slowly with the combination of the two drugs than with either Trimethoprim or Sulfamethoxazole alone.

Source: Drug Bank

Food Interaction

Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.|Take on empty stomach: 1 hour before or 2 hours after meals.|Take with a full glass of water.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. The metabolism of sulfamethoxazole occurs predominately by N4-acetylation, although the glucuronide conjugate has been identified.

Source: Drug Bank

Protein Binding

70%

Source: Drug Bank

Absorption

Rapidly absorbed following oral administration. Also well-absorbed topically.

Source: Drug Bank

Half-Life

10 hours

Source: Drug Bank

Toxicity

Sulfamethoxazole may cause nausea, vomiting, diarrhea and hypersensitivity reactions. Hematologic effects such as anemia, agranulocytosis, thrombocytopenia and hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency may also occur. Sulfamethoxazole may displace bilirubin from albumin binding sites causing jaundice or kernicterus in newborns.

Source: Drug Bank

Chemical Properties

Chemical Formula

C10H11N3O3S

Source: Drug Bank

Isomeric SMILES

c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N

Source: OpenEye

Canonical SMILES

CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1

Source: PharmGKB

Average Molecular Weight

253.278

Source: Drug Bank

Monoisotopic Molecular Weight

253.052111923

Source: Drug Bank

SMILES

CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1

Source: Drug Bank

InChI String

InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Interactions

Interaction Description
chlorpropamide - sulfamethoxazole Sulfonamide/sulfonylurea: possible hypoglycemia (source: Drug Bank)
chlorpropamide - sulfamethoxazole Sulfonamide/sulfonylurea: possible hypoglycemia (source: Drug Bank)
cyclosporine - sulfamethoxazole The sulfonamide decreases the effect of cyclosporine (source: Drug Bank)
cyclosporine - sulfamethoxazole The sulfonamide decreases the effect of cyclosporine (source: Drug Bank)
methotrexate - sulfamethoxazole The sulfamide increases the toxicity of methotrexate (source: Drug Bank)
methotrexate - sulfamethoxazole The sulfamide increases the toxicity of methotrexate (source: Drug Bank)
tolbutamide - sulfamethoxazole Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank)
tolbutamide - sulfamethoxazole Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank)
warfarin - sulfamethoxazole Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to sulfamethoxazole: 40

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antimicrobial agents. Pharmacogenomics. 2014. Aung Ar Kar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenetics and genomics. 2012. Sacco James C, et al. PubMed
Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrobial agents and chemotherapy. 2012. Kagaya Hideaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annual review of pharmacology and toxicology. 2012. Bharadwaj Mandvi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. BMC medical genomics. 2012. Wang Danxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenetics and genomics. 2011. Wang Danxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prevalence of G6PD deficiency in a large cohort of HIV-infected patients. The Journal of infection. 2010. Serpa Jose A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010. Chisholm-Burns Marie A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Yasuda Kazuto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Diagnosis and management of HIV drug hypersensitivity. The Journal of allergy and clinical immunology. 2008. Davis Carla M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenetics and genomics. 2008. Lonjou Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008. Cappellini M D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002). 2008. Tungsiripat Marisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. The pharmacogenomics journal. 2007. Fuselli S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pneumocystis carinii pneumonia in Hong Kong: a 10 year retrospective study. Journal of medical microbiology. 2006. Hui M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. British journal of clinical pharmacology. 2003. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (New York, N.Y.). 2002. Splawski Igor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. Journal of clinical pharmacology. 2002. O'Neil William M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics. 2000. Wolkenstein P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics. 2000. Pirmohamed M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America. 2000. Sesti F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. European journal of clinical pharmacology. 1998. ZieliƄska E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. Journal of pharmacokinetics and biopharmaceutics. 1996. Spielberg S P. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clinical pharmacology and therapeutics. 1996. Kaufmann G R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Southern medical journal. 1996. Korraa H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians. 1996. Reinke C M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. The Journal of pharmacology and experimental therapeutics. 1995. Nakamura H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
G6PD deficiency. Blood. 1994. Beutler E. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS (London, England). 1994. Carr A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Reviews of infectious diseases. 1987. Markowitz N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Co-trimoxazole in the treatment of typhoid fever in children with glucose-6-phosphate dehydrogenase deficiency. The Southeast Asian journal of tropical medicine and public health. 1978. Lexomboon U, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. British medical journal. 1976. Chan T K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Letter: Glucose-6-phosphate dehydrogenase deficiency and co-trimoxazole. Lancet. 1975. Chan M C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haemolytic effect of trimethoprim-sulphamethoxazole in G-6-PD deficiency. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1974. Chan T K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A comparative evaluation of sulfalene-trimethoprim and sulphormethoxine-pyrimethamine against falciparum malaria in Thailand. The American journal of tropical medicine and hygiene. 1973. Chin W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Acute haemolysis associated with typhoid fever and G.-6-P.D. deficiency. Lancet. 1973. Meyer H A. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Acute haemolysis complicating co-trimoxazole therapy for typhoid fever in a patient with G.-6-P.D. deficiency. Lancet. 1972. Owusu S K. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The importance of glucose-6-phosphate dehydrogenase screening in a urologic practice. The Journal of urology. 1972. Allen S D, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01015
ChEBI:
9332
KEGG Compound:
C07315
KEGG Drug:
D00447
PubChem Compound:
5329
PubChem Substance:
156228
46508111
Drugs Product Database (DPD):
421480
ChemSpider:
5138
Therapeutic Targets Database:
DNC001393

Clinical Trials

These are trials that mention sulfamethoxazole and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.